Welcome to LookChem.com Sign In|Join Free

CAS

  • or
1-(4-Methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester is a chemical compound that belongs to the family of pyrazolo[3,4-c]pyridine derivatives. It is characterized by its molecular formula C17H18N2O4 and a molecular weight of 314.33 g/mol. 1-(4-Methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester is known for its potential as a synthetic intermediate in the pharmaceutical industry, and it may also hold promise in medicinal chemistry and drug discovery due to its unique chemical structure and possible biological activities. Further research and testing are required to fully elucidate its properties and potential applications.

503614-56-0 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 1-(4-Methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester

    Cas No: 503614-56-0

  • USD $ 1.9-2.9 / Gram

  • 100 Gram

  • 1000 Metric Ton/Month

  • Chemlyte Solutions
  • Contact Supplier
  • 1-(4-Methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester

    Cas No: 503614-56-0

  • USD $ 10.0-10.0 / Milligram

  • 1 Milligram

  • 100000000 Kilogram/Month

  • weifang yangxu group co.,ltd
  • Contact Supplier
  • 503614-56-0 Structure
  • Basic information

    1. Product Name: 1-(4-Methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester
    2. Synonyms: ethyl 1-(4-methoxyphenyl)-7-oxo-5,6-dihydro-4H-pyrazolo[3,4-c]pyridine-3-carboxylate;Ethyl 1-(4-methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate;1-(4-Methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester
    3. CAS NO:503614-56-0
    4. Molecular Formula: C16H17N3O4
    5. Molecular Weight: 315
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 503614-56-0.mol
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: 588.554 °C at 760 mmHg
    3. Flash Point: 309.747 °C
    4. Appearance: /
    5. Density: 1.36
    6. Refractive Index: N/A
    7. Storage Temp.: 2-8°C
    8. Solubility: N/A
    9. PKA: 13.81±0.20(Predicted)
    10. CAS DataBase Reference: 1-(4-Methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester(CAS DataBase Reference)
    11. NIST Chemistry Reference: 1-(4-Methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester(503614-56-0)
    12. EPA Substance Registry System: 1-(4-Methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester(503614-56-0)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 503614-56-0(Hazardous Substances Data)

503614-56-0 Usage

Uses

Used in Pharmaceutical Industry:
1-(4-Methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester is used as a synthetic intermediate for the production of various pharmaceuticals. Its unique chemical structure allows it to be a key component in the synthesis of new drugs, potentially leading to the development of novel therapeutic agents.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 1-(4-Methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester is utilized for its potential to contribute to the discovery of new drugs. Its chemical properties and structure make it a valuable candidate for further exploration and optimization in drug design.
Used in Drug Discovery:
1-(4-Methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester is employed in drug discovery processes to identify and develop new chemical entities with potential therapeutic applications. Its unique features and interactions with biological targets may lead to the creation of innovative medications for various diseases and conditions.

Check Digit Verification of cas no

The CAS Registry Mumber 503614-56-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,0,3,6,1 and 4 respectively; the second part has 2 digits, 5 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 503614-56:
(8*5)+(7*0)+(6*3)+(5*6)+(4*1)+(3*4)+(2*5)+(1*6)=120
120 % 10 = 0
So 503614-56-0 is a valid CAS Registry Number.

503614-56-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 20, 2017

Revision Date: Aug 20, 2017

1.Identification

1.1 GHS Product identifier

Product name ethyl 1-(4-methoxyphenyl)-7-oxo-5,6-dihydro-4H-pyrazolo[3,4-c]pyridine-3-carboxylate

1.2 Other means of identification

Product number -
Other names Y6612

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:503614-56-0 SDS

503614-56-0Downstream Products

503614-56-0Relevant articles and documents

Preparation method of apixaban and intermediates thereof

-

Paragraph 0082-0097, (2018/05/16)

The invention discloses a preparation method of apixaban and intermediates thereof. The invention provides a preparation method of an apixaban intermediate I. The preparation method of the apixaban intermediate I comprises the step of performing nucleophilic substitution reaction on an apixaban intermediate II and p-fluoronitrobenzene in an organic solvent in the presence of an alkali to obtain the apixaban intermediate I. The preparation method has short steps, simple and safe operation, simple post-treatment steps, environmental friendliness and high total yield, and the obtained product hashigh purity, low production cost and high atomic utilization, and is suitable for industrial production. The formula is shown in the description.

Pyrazolo [3, 4 - c] pyridine - 7 - ketone compound and use thereof

-

, (2017/09/01)

Belonging to the technical field of medicine, the invention relates to a 4, 5-dihydro-1H-pyrazolo[3, 4-c]pyridine-7-one containing derivative shown as general formula I, and pharmaceutically acceptable salt, hydrate or prodrug thereof, wherein the substituents A, R1 and R2 have meanings given in the specification. The preparation also relates to a preparation method of the general formula I compound and its pharmaceutically acceptable salt or prodrug, medicinal compositions containing the compound and application of the compound as an Xa factor inhibitor, especially application in preparation of drugs for treatment and/or prevention of thromboembolic diseases. (formula I).

LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS

-

Paragraph 0765, (2017/04/28)

The present application describes lactam-containing compounds and derivatives thereof of Formula I: P4—P-M-M4??I or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR

-

Paragraph 0083, (2017/04/11)

Provided is a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X is selected from a 3-9 membered carbon ring or its phenyl ring, and a 4-10 membered heterocyclic ring or its benzo ring; Y and Z are independently selected from 4-9 membered saturated heterocyclic rings respectively; RI-3 are independently selected from H, F, Cl, Br, I, CN, OH, SH,NH2, CHO, COOH respectively, or selected from C1-10 alkyls or heteroalkyls optionally substituted by R01, C3-10 alkyls ring hydrocarbon groups or heterocyclic hydrocarbon groups, C1-10 alkyls or heteroalkyls substituted by C3-10 ring hydrocarbon groups or heterocyclic hydrocarbon group. The compound can be used as an anticoagulant for treating and preventing thrombotic disorders, and can meet the real needs of selectivity and a potent inhibitor for coagulation Xa.

A morpholine-free process amenable convergent synthesis of apixaban: a potent factor Xa inhibitor

Nevuluri, Narasimha Rao,Rapolu, Rajesh Kumar,Iqbal, Javed,Kandagatla, Bhaskar,Sen, Saikat,Dahanukar, Vilas H.,Oruganti, Srinivas

, p. 1477 - 1482 (2017/07/18)

A convergent synthesis of the anti-coagulant drug apixaban has been efficiently demonstrated on a multi-gram scale. The synthetic route is noteworthy for its brevity and fact that it completely avoids the use of morpholine, a toxic and flammable reagent, in constructing the 5,6-dihydro-1H-pyrazolo[3,4-c]pyridin-7(4H)-one core present in apixaban. Graphical abstract: [Figure not available: see fulltext.].

Containing a lactam substituent pyrazole piperidine ketone compound, and its composition and use thereof

-

Paragraph 0160; 0161; 0162, (2016/10/08)

The present invention relates to a pyrazolo piperidone compound and a pharmaceutically acceptable composition thereof and use thereof in preparation of medicines for treating Xa-factor associated diseases, and particularly relates to a novel lactam substituent-containing pyrazolo piperidone compound and a pharmaceutical composition containing the compound and use of the compound in preparation of the medicines for the treating Xa-factor associated diseases.

Pyrazole substituent comprising cyclonexane and piperidine ketone compound, and its composition and use thereof

-

Paragraph 0145; 0146; 0159; 0160; 0161, (2016/10/08)

The invention relates to a pyrazolo piperidone compound and a pharmaceutically acceptable composition thereof and application thereof to preparation of medicaments for treating diseases associated with an Xa factor. In particular, the invention relates to a novel pyrazolo piperidone compound containing a cyclohexane substituent, the pharmaceutical composition containing the compound, and application of the compounds to preparation of medicaments for treating diseases associated with the Xa factor.

Aromatic ring containing substituted methyl substituted pyrazole piperidine ketone compound, and its composition and use thereof

-

Paragraph 0164; 0165; 0166, (2016/10/09)

The invention relates to pyrazolopiperidone compounds, pharmaceutically-acceptable salts of the compounds and use of the compounds in preparation of medicines for treating Xa factor related diseases. Particularly, the invention relates to novel methyl substituted aromatic ring substituent-containing pyrazolopiperidone compounds, pharmaceutical compositions containing the compounds and use of the compounds in the preparation of the medicines for treating the Xa factor related diseases.

Containing thiazole pyrazole piperidine ketone compound, and its composition and use thereof

-

Paragraph 0156; 0157, (2016/10/10)

The invention relates to a pyrazolo piperidone compound and a pharmaceutically acceptable composition thereof and application thereof to preparation of medicaments for treating diseases associated with an Xa factor. In particular, the invention relates to a novel pyrazolo piperidone compound containing thiazole, the pharmaceutical composition containing the compound, and application of the compounds to preparation of medicaments for treating diseases associated with the Xa factor.

Containing substituted butynyl pyrazole piperidine ketone compound, and its composition and use thereof

-

Paragraph 0160; 0161; 0162, (2016/10/10)

The invention relates to pyrazolopiperidone compounds, pharmaceutically-acceptable salts of the compounds and use of the compounds in preparation of medicines for treating Xa factor related diseases. Particularly, the invention relates to novel substitute butynyl-containing pyrazolopiperidone compounds, pharmaceutical compositions containing the compounds and use of the compounds in the preparation of the medicines for treating the Xa factor related diseases.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 503614-56-0